Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea
| Autor: | Sezaneh Haghpanah, Azin Hamidi, Mehran Karimi, Marzieh Bardestani, Maryam Khavari, Mohammad Hadi Bagheri, Razieh Hantooshzadeh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Ineffective erythropoiesis
medicine.medical_specialty Southern Iran business.industry Thalassemia General Medicine Gallstones medicine.disease_cause Bioinformatics medicine.disease Gastroenterology Hemolysis Kowsar Bone marrow suppression Cholelithiasis Internal medicine Beta Thalassemia Intermedia medicine Hydroxyurea In patient business Research Article |
| Zdroj: | Iranian Red Crescent Medical Journal |
| ISSN: | 2074-1812 2074-1804 |
| Popis: | Background: Recent studies regarding the effect of hydroxyurea (HU) in thalassemia have revealed favorable effects on the reduction of ineffective erythropoiesis. Objectives: The aim of the current study was to evaluate whether or not HU can have an effect on the gallstone formation rate in patients with beta-thalassemia intermedia (BTI). Patients and Methods: In this case control cross-sectional study, from a total of 250 transfusion-independent BTI patients, 51 patients who were taking HU, participated in the study. Patients were registered in the Thalassemia clinic of Shiraz University of Medical Sciences, Shiraz, which is a referral center located in southern Iran, during 2011-2012. Mean dose of HU consumption in the case group was 10 ± 2.5 mg/kg/day (range of 8-15 mg/kg/day), with a mean duration of consumption of 7.5 ± 3.8 years (range 1-14 years). In addition, 41 age- and sex-matched BTI patients who did not use HU were randomly selected as a control group. All patients underwent abdominal ultrasound by a radiologist for evaluation of gallstones. Results: Mean age of the participants was 21.4 ± 6.5 years (10-40 years). There was no statistically significant difference regarding the frequency of cholelithiasis between the two groups of patients (P = 0.822). Our study showed significantly lower hemoglobin levels and a higher percentage of nucleated red blood cells in the HU group compared with the control group (P = 0.001 and P = 0.005, respectively). Conclusions: It seems that taking HU for long periods can reduce hemolysis and bone marrow suppression, and that decreases the rate of cholelithiasis. We believe that if these patients had not been treated with HU, we would probably have observed a significantly higher frequency of cholelithiasis, due to more hemolysis compared with patients not taking HU. Further studies with larger sample sizes are suggested. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|